Loading
ArriVent Biopharma, Inc. Stock: price and insider trades · United States
US·Mcap US$1.4B
ArriVent Biopharma, Inc.: what insiders have been doing
Insider filings for ArriVent Biopharma, Inc. are scarce in the SEC (Form 4) feed, the latest one published on 3 February 2026. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€11M
1 ops. · all time
Who traded when
BuySaleHillhouse Investment Management, Ltd.1 sale
Analyst consensus: bullish or bearish?
Analysts rate ArriVent Biopharma, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$44.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$30.84
Analyst consensus
10 analystsStrong buy
US$42.00Target US$44.60(+45%)US$50.00
Income statement
EBITDA-US$177.5M
Net income-US$166.3M0.0% margin
Valuation
PER (forward)-8.9x
P/Book4.3x
Beta1.37
Balance sheet & cash
Market capUS$1.4B
Total debtUS$14k
Free Cash Flow-US$160.6M
Debt / Equity0%
Profitability & ownership
ROE-55.2%
ROA-34.7%
% insiders1.6%
% institutions98.4%
Last declaration on 3 February 2026
Declarations9 total
555,555 shares@ US$23.37100.0% of flowCommon StockSEC:0000902664-26-000675:0
2,050 shares@ US$2.2810.8% of flowCommon StockSEC:0001104659-25-067928:0
2,600 shares@ US$2.2813.8% of flowCommon StockSEC:0001104659-25-067928:1
6,503 shares@ US$2.2834.4% of flowCommon StockSEC:0001104659-25-067928:2
2,700 shares@ US$6.2441.0% of flowCommon StockSEC:0001104659-24-102146:0
3,616,041 sharesCommon StockSEC:0000902664-24-000903:0
821,827 sharesCommon StockSEC:0001104659-24-008799:0
1,252,308 sharesCommon StockSEC:0001104659-24-008796:0
821,827 sharesCommon StockSEC:0001104659-24-008797:0
9 of 9 declarations
About ArriVent Biopharma, Inc.
ArriVent Biopharma, Inc. is a biopharmaceutical company focused on developing innovative treatments for respiratory diseases. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
